{
  "id": "64402e7757b1c7a315000044",
  "type": "factoid",
  "question": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.",
  "ideal_answer": "Each cohort of the phase I/II double-blind, comparator-controlled trial of RT001 involved 9 Friedreich's ataxia patients. In total nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
  ],
  "snippets": [
    {
      "text": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Nine per cohort, 9/cohort, 18 in total"
}